Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy

People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according to a brief report published online Feb. 12 in JAMA Ophthalmology.

source https://medicalxpress.com/news/2026-02-semaglutide-nonarteritic-anterior-ischemic-optic.html